Ignite Creation Date:
2025-12-24 @ 7:25 PM
Ignite Modification Date:
2025-12-25 @ 5:05 PM
Study NCT ID:
NCT03708003
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-27
First Post:
2018-10-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Sponsor:
Swiss Cancer Institute